Anixa Biosciences, Inc.
Company Snapshot: Anixa Biosciences, Inc.
Anixa, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. It is developing the Cchek™ platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization. Additional information is available at www.anixa.com.
- Jun 1 2020 Anixa Biosciences and OntoChem Have Synthesized Four Potential Covid-19 Drugs for Testing in Biological Assays
- May 4 2020 Anixa Biosciences and OntoChem Announce Discovery of First Covid-19 Therapeutic Candidate
- Apr 23 2020 Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Biomarker Insights Highlighting Cchek™ Liquid Biopsy Technology
- Apr 20 2020 Anixa Biosciences and OntoChem Announce Collaboration to Develop Novel COVID-19 Therapeutics